Document Detail


Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy.
MedLine Citation:
PMID:  9109894     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tiagabine blocks the uptake by neurons or glia of synaptically released GABA resulting in prolonged GABAergic activity and decreased likelihood of epileptic seizures. We evaluated the cognitive and quality of life effects of tiagabine in a double-blind, add-on, placebo-controlled, parallel, multicenter, dose-response efficacy study in patients with focal epilepsy whose complex partial seizures were difficult to control. One hundred sixty-two patients provided cognitive and quality of life data for the analyses and received the following treatments: placebo (n = 57), 16 mg/d tiagabine (n = 34), 32 mg/d tiagabine (n = 45), or 56 mg/d tiagabine (n = 26) at a fixed-dose for 12 weeks after a 4-week dose titration period. Eight cognitive tests and three measures of mood and adjustment were administered during the baseline period and again during the double-blind period near the end of treatment (or at the time of dropout). The patient groups were similar at entry into the study. Results showed no clinically important changes with the addition of tiagabine on the test battery. Although this is an encouraging finding, it remains for future investigations to determine the cognitive and behavioral effects of tiagabine either as monotherapy or in relation to other antiepileptic drugs.
Authors:
C B Dodrill; J L Arnett; K W Sommerville; V Shu
Related Documents :
2846824 - Behavioral tolerance and sensitization to cgs 19755, a competitive n-methyl-d-aspartate...
17481604 - Chronically administered fluoxetine enhances the anticonvulsant activity of conventiona...
12007674 - Niguldipine impairs the protective activity of carbamazepine and phenobarbital in amygd...
7938564 - Strychnine-induced seizures in mice: the role of noradrenaline.
10555124 - Phase i clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (nsc 3...
19299154 - Regulatory implications of a linear non-threshold (lnt) dose-based risks.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neurology     Volume:  48     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1997 Apr 
Date Detail:
Created Date:  1997-05-15     Completed Date:  1997-05-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1025-31     Citation Subset:  AIM; IM    
Affiliation:
Department of Neurology, University of Washington School of Medicine, Seattle, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Anticonvulsants / administration & dosage*,  therapeutic use
Cognition*
Dose-Response Relationship, Drug
Double-Blind Method
Epilepsy, Complex Partial / drug therapy*,  physiopathology,  psychology*
Female
Humans
Male
Middle Aged
Nipecotic Acids / administration & dosage*,  therapeutic use
Quality of Life*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticonvulsants; 0/Nipecotic Acids; 115103-54-3/tiagabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Proton spectroscopic imaging at 4.1 tesla in patients with malformations of cortical development and...
Next Document:  A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial ...